Lupin to acquire German firm’s product portfolio

A day after announcing its biggest buy of $880 million, Lupin said that it will buy Germany-based Temmler Pharma’s specialty product portfolio. India’s third largest drug maker by sales has entered into a strategic asset purchase agreement with Temmler Pharma, part of the <g data-gr-id="35">Aenova</g> Group, one of the world’s largest pharmaceutical contract manufacturers, to acquire its specialty 

product  portfolio.

The announcement came just a day after, the Mumbai-based company inked a deal to buy US-based <g data-gr-id="34">Gavis</g> Pharmaceuticals for USD 880 million (Rs 5,610 crore) - its largest acquisition so far to expand in the US generics market.

Lupin CEO Vinita Gupta said, “We are very pleased to add to our specialty business with this 

acquisition. <g data-gr-id="36">Temmler’s</g> business has a strong strategic fit with Lupin’s <g data-gr-id="37">Hormosan</g> business in Germany and enables Lupin to bring an enhanced specialty CNS portfolio to the German market.”

Based in Marburg (Germany), <g data-gr-id="32">Temmler</g> has a specialty portfolio of 13 products including key Central Nervous System products and specialty products that address rare disease areas like Myasthenia Gravis, Huntington disease as well as fast-growing dermatology products for <g data-gr-id="33">anti-wart</g> treatment.

“<g data-gr-id="30">Temmler</g> is a profitable pharmaceutical player backed by a strong and experienced management team that is also taken on and which will strongly support our future growth plans,” Lupin, President-Europe and Head of Inhalation Strategy Maurice <g data-gr-id="31">Chagnaud</g> said. 

<g data-gr-id="27">Aenova</g> Group CFO Frank Elsen said Lupin is perfectly poised to take <g data-gr-id="28">Temmler’s</g> product portfolio and its growth forward. “We are extremely optimistic about this strategic agreement which allows us to concentrate on our core business.”